APA (7th ed.) Citation

Lan, T., Zhu, Y., Zhong, W., Tan, Q., Lin, T., Huang, J., & He, W. (2025). Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: Study protocol of a multicenter single-arm phase II trial. BMC cancer, 25(1), 868-8. https://doi.org/10.1186/s12885-025-14234-5

Chicago Style (17th ed.) Citation

Lan, Tianhang, Yingying Zhu, Wenlong Zhong, Qihong Tan, Tianxin Lin, Jian Huang, and Wang He. "Evaluating the Efficacy and Safety of Bladder-sparing Regimen with Disitamab Vedotin Combined with Toripalimab and Pelvic Lymph Node Dissection in Muscle-invasive Bladder Cancer Patients: Study Protocol of a Multicenter Single-arm Phase II Trial." BMC Cancer 25, no. 1 (2025): 868-8. https://doi.org/10.1186/s12885-025-14234-5.

MLA (9th ed.) Citation

Lan, Tianhang, et al. "Evaluating the Efficacy and Safety of Bladder-sparing Regimen with Disitamab Vedotin Combined with Toripalimab and Pelvic Lymph Node Dissection in Muscle-invasive Bladder Cancer Patients: Study Protocol of a Multicenter Single-arm Phase II Trial." BMC Cancer, vol. 25, no. 1, 2025, pp. 868-8, https://doi.org/10.1186/s12885-025-14234-5.